The systemic immune-inflammation index (SII) was found to be a potential predictor of the prognosis of patients with chronic obstructive pulmonary disease (COPD).
High systemic immune-inflammation index (SII) is closely linked to an elevated risk of respiratory failure (RF) and death in patients with chronic obstructive pulmonary disease (COPD), according to a study published in the International Journal of Chronic Obstructive Pulmonary Disease.
The researchers explained that RF, especially hypercapnic RF (HRF) frequently occurs in patients with severe or end-stage COPD; COPD complicated by RF (COPD+RF) increases the difficulty of treatment, resulting in poor prognosis and unplanned hospitalization. Due to the negative influence COPD+RF has on patients’ health and quality of life, the researchers claimed that early RF risk identification in patients with COPD is important to implement preventative strategies as early as possible. To do so, they need an easily accessible biomarker related to RF incidence to predict patients’ clinical outcomes.
The researchers noted that one potentially useful biomarker could be SII, “a comprehensive inflammatory indicator that is computed by peripheral lymphocyte, neutrophil, and platelet counts.” They explained that SII is regarded as a powerful inflammatory indicator of both local immune response and systemic inflammation, and it has been indicative of poor prognosis or stroke, cardiovascular diseases, acute kidney injury, and sepsis. However, no study has been conducted to understand how SII influences the prognosis of critically ill patients with COPD.
Therefore, the researchers conducted a study to analyze the relationship between SII and the risk of RF and death in critically ill patients with COPD; it also assessed the prognostic value of SII in this population, guiding the prevention and treatment of COPD+RF. More specifically, the primary outcome analyzed was the incidence of RF, and the secondary outcomes investigated were in-hospital all-cause mortality and mortality during long-term follow-up.
To do so, the researchers retrospectively acquired relevant data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV), a sizable, open-access database that includes the clinical data of 299,712 patients hospitalized in the Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019.
They included adult patients diagnosed with COPD according to the ninth and 10th revisions of the International Classification of Diseases (ICD-9, ICD-10). Conversely, the researchers excluded patients who had RF at admission, patients hospitalized for less than 24 hours, and patients whose platelet, lymphocyte, and neutrophil counts were missing or 0.
Initially, the researchers retrospectively extracted 14,050 patients with COPD from the MIMIC-IV database, but they ultimately analyzed 1653; the study population consisted of 879 (53.2%) males and 774 (46.8%) females. The study population's average age was 71.0 years (range, 62.0-78.0 years), and the average SII was 1302.17 (range, 634.51-2821.88). The researchers noted that patients with a high SII were mostly older White males with more unstable vital signs and higher disease scores at admission.
Additionally, RF occurred in 697 (42.2%) patients, and HRF occurred in 427 (25.8%) patients. Also, 169 patients died in the hospital, with 130 (7.9%) deaths in the intensive care unit (ICU) and 39 (2.3%) deaths during hospitalization; the researchers determined that 637 (38.5%) patients died during follow-up. Lastly, they explained that the median follow-up time for RF, in-hospital death, and follow-up death was 5.0 (range, 1.0-9.0), 8.0 (range, 5.0-15.0), and 29.0 (range, 8.0-187.0) days, respectively.
Overall, the researchers determined that SII is linked to an elevated risk of RF and death in patients with COPD. Their findings showed that higher SII increased patients’ risk of RF (HR, 1.19; 95% CI, 1.12-1.28; P < .001), in-hospital mortality (HR, 1.22; 95% CI, 1.07-1.39; P = .003), and long-term follow-up mortality (HR, 1.12; 95% CI, 1.05-1.19; P < .001). More specifically, a Kaplan-Meier analysis suggested a significantly elevated risk of all-cause death (log-rank P < .001) in patients with higher SII, especially during the short-term follow-up period of 21 days.
The researchers acknowledged their study’s limitations, one being that it has a single-center retrospective design. Therefore, the study population was subject to selection bias, resulting in the limited generalizability of their findings to other populations. Despite its limitations, the researchers expressed confidence in their findings, making future research suggestions based on them.
“…SII serves as a potential, cost-effective, and easily available biomarker for early risk assessment of this population,” the authors concluded. “Nevertheless, larger prospective studies with long-term follow-up are desired to corroborate our conclusions.”
Reference
Zhang Y, Tan X, Hu S, Cui Z, Chen W. Relationship between systemic immune-inflammation index and risk of respiratory failure and death in COPD: a retrospective cohort study based on the MIMIC-IV database. Int J Chron Obstruct Pulmon Dis. 2024;19:459-473
doi:10.2147/COPD.S446364
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
May 21st 2024A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Patients With COPD, PRISm at Increased All-Cause, Cause-Specific Mortality Risk
May 20th 2024Patients with chronic obstructive pulmonary disease (COPD) and/or preserved ratio impaired spirometry (PRISm) have an increased risk of all-cause and cause-specific mortality, highlighting the need for better understanding of these conditions through increased spirometry data collection.
Read More